As COVID-19 continues to impact every aspect of the healthcare and financial sectors, consumers around the country are confronting an uncertain economic climate while also addressing some familiar challenges—including the ever-increasing cost of prescription drugs.
Pharmaceutical Industry News
Prism Health Lab - a branch of the 30+-year-old Prism Group of Companies - has launched its sixth location in as many months in the Chinatown neighborhood of Chicago by leveraging Prism's unique digital technology developed to enable large scale and cost-effective testing.
OpenEye Scientific and Sygnature Discovery – a world-leading integrated discovery and pre-clinical solutions provider – today announced the adoption of OpenEye's Orion™ platform to power Sygnature's computational efforts in molecular design drug discovery solutions.
SAS, the leader in advanced analytics, will extend a 40-year partnership with the US Food and Drug Administration (FDA) to expand its capabilities in natural language processing, artificial intelligence and machine learning capabilities through the SAS® Viya® platform in support of the FDA's mission as an essential public health agency.
Genesis Biotechnology Group® (GBG) and its Contract Research Organization (CRO) arm Genesis Drug Discovery & Development™ (GD3) announced today that it has acquired the Cincinnati-based CRO STATKING Clinical Services.
Mott now offers drug diffusion studies to help guide the design criteria for your next generation, controlled release drug delivery technology.
A study conducted by Millennium Health and published in Drug and Alcohol Dependence highlights the role real-time urine drug test results can play in identifying dangerous drug abuse trends including fentanyl analog positivity nationwide. Up to 10,000-fold more potent that morphine,1 fentanyl analogs can pose a serious risk for overdose.
The former heads of Canada's most recognized domestic pharmaceutical companies have united to help combat the mental health crisis expected to impact Canadians long after the COVID-19 pandemic.
Frost & Sullivan's recent analysis, Hybridization of Clinical Trial Designs Reviving Global CRO Market Post-pandemic; 2019-2024, reveals that hybrid clinical trials and remote patient monitoring are key trends driving the global contract research organization (CRO) market.
Croma is always committed to deepening its product portfolio to support customers in their daily work. With pure HA, Croma has developed a highly concentrated liquid skin mask in a minimalistic formula containing 1.8% of hyaluronic acid to smooth, moisturize and revitalize the skin while boosting its natural hydration.